1. 380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors. (9th November 2020) Authors: Hong, David; Patel, Sandip; Patel, Manish; Musni, Kimberly; Anderson, Marlisa; Cooley, Sarah; Valamehr, Bahram; Chu, Wayne Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors. (10th December 2020) Authors: Hong, David; Patel, Sandip; Patel, Manish; Musni, Kimberly; Anderson, Marlisa; Cooley, Sarah; Valamehr, Bahram; Chu, Wayne Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗